CD274 and neoplasm: One of the limitations of using PD-L1 IHC TPS ≥ 1% as the cut-off in the tumour types without a CDx indication is that there is a lack of data on clinical outcomes in patients treated with immunotherapy using this PD-L1 cut-off; therefore, this analysis was considered exploratory67.